Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• metabolic syndrome which is characterized by a group of metabolic risk factors in one person. They include: (a) central obesity, indicated by excessive fat tissue in and around the abdomen; (b) atherogenic dyslipidemia (blood fat disorders, mainly high triglycerides and low HDL cholesterol, that foster plaque buildups in artery walls); (c) elevated blood pressure (130/85 mmHg or higher); (d) insulin resistance or glucose intolerance (the body can't properly use insulin or blood sugar); (e) prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor [-1] in the blood); and (f) pro-inflammatory state (e.g., elevated high-sensitivity C-reactive protein in the blood).
• central obesity indicated by excessive fat tissue in and around the abdomen
• atherogenic dyslipidemia blood fat disorders, mainly high triglycerides and low HDL cholesterol, that foster plaque buildups in artery walls
• elevated blood pressure 130/85 mmHg or higher
• insulin resistance or glucose intolerance the body
• Metabolic syndrome has become increasingly common in the United States. It is estimated that about 20- 25 percent of US adults are affected. The syndrome is closely associated with a generalized metabolic disorder called insulin resistance, in which the body cannot use insulin efficiently. Metabolic syndrome is also called insulin resistance syndrome, which leads to Type 2 diabetes.
• bioflavonoids isolated from various plants.
• the potential role of bioflavonoids in the prevention of cancers and cardiovascular disease and the treatment of inflammatory diseases has been documented.
• Thousands of naturally occurring bioflavonoids derived from various plants have been classified according to their chemical structure. These classes are flavones, isoflavones, flavan-3-ols and anthocyanidins.
• Flavones are divided into four groups: (1 ) flavones, which include, e.g., luteolin, apigenin and tangeritin; (2) flavonols, which include, e.g., quercetin, kaempferol, myricetin, chrysin, rutin, rhoifolin, morin, fisetin, isorhamnetin, pachypodol and rhamnazin; (3) flavanones, which include, e.g., galangin, hesperetin, naringenin, naringin, neohesperidin, hesperidin, narirutin, pruning, eriodictyol, homoeriodictyol; and (4) 3-hydroxyflavanones or 2,3-dihydroflavonols, which include, e.g., dihydroquercetin and dihydrokaempferol.
• isoflavones include, e.g., genistein, daidzein and glycitein.
• Flavan-3-ols include, e.g., catechins, gallocatechin, catechin 3-gallate, gallocatechin 3-gallate, epicatechins, epigallocatechin, epicatechin 3-gallate and epigallocatechin 3-gallate.
• Anthocyanidins include, e.g., cyanidin, delphinidin, malvidin, perlargonidin, peionidin and petunidin.
• Flavonoid availability and activity varies greatly among the natural sources of flavonoids. In order to obtain the healthful benefits of many flavonoids, large doses are required, which is often impractical and too costly.
• a composition for treating diabetes and metabolic disorders is also useful for achieving weight loss and weight control by preventing much of the calories of a carbohydrate- containing food from having an impact.
• Consumption of the composition with a carbohydrate-containing foodstuff affects the metabolic pathways of carbohydrate metabolism, resulting in less glucose getting into the body and more glucose in the bloodstream getting shunted to the muscles.
• Consumption of the composition by a subject promotes an increase in the ratio between lean and adipose tissue in the subject.
• the present invention provides a composition and a method for treating or preventing diabetes and/or obesity using a combination of naturally occurring compounds.
• the method comprises administering to a subject a composition comprising therapeutically effective amounts of quercetin, myricetin and chlorogenic acid.
• the composition may be administered as a dietary supplement or as an additive to a foodstuff.
• the composition is effective in interrupting the metabolic pathways of carbohydrate metabolism. Specifically, the composition is effective in inhibiting glucose absorption in the gut, enhancing glucose absorption by muscle tissue, inhibiting carbohydrate transport, inhibiting glucose/fat storage and inhibiting the manufacture of glucose by the liver (gluconeogenesis).
• composition and method for lowering the glycemic index of a carbohydrate-containing foodstuff by adding to the foodstuff effective amounts of quercetin, myricetin and chlorogenic acid.
• the ratio of chlorogenic acid to quercetin to myricetin is about 1 :3:3 by weight.
• Diabetes refers to high blood sugar or ketoacidosis, as well as chronic, general metabolic abnormalities arising from a prolonged high blood sugar status or a decrease in glucose tolerance. “Diabetes” encompasses both the Type 1 and Type 2 (Non Insulin Dependent Diabetes Mellitus or NIDDM) forms of the disease.
• Type 1 and Type 2 Non Insulin Dependent Diabetes Mellitus or NIDDM
• isolated refers to the removal or change of a composition or compound from its natural context.
• naturally occurring when referring to a compound means a compound that is in a form in which it can be found naturally.
• a compound is not in a form that is naturally occurring if, for example, the compound has been purified and separated from at least some of the other molecules that are found with the compound in nature.
• a “naturally occurring compound” refers to a compound that can be found in nature, i.e., a compound that has not been designed by man.
• a naturally occurring compound may have been made by man or by nature.
• “Treating" a condition or disease refers to curing as well as ameliorating at least one symptom of the condition or disease.
• therapeutic effect is art-recognized and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans caused by a pharmacologically active substance.
• therapeutically effective amount means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment.
• the therapeutically effective amount of such substance will vary depending upon the subject and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, the manner of administration and the like, which can readily be determined by one or ordinary skill in the art.
• certain compositions described herein may be administered in a sufficient amount to produce a desired effect at a reasonable benefit/risk ratio applicable to such treatment.
• the glycemic index (Gl) is a ranking of carbohydrates on a scale from 0 to
• Foods with a high Gl are those that are rapidly digested and absorbed and result in marked fluctuations in blood sugar levels.
• High Gl foods include bread, rice, cereal and baked goods.
• Low Gl (i.e., 55 or less) foods are slowly digested and absorbed and result in gradual rises in blood sugar and insulin levels.
• Low Gl foods include fruits, vegetables, whole grains and legumes.
• Low Gl diets have been shown to improve both glucose and lipid levels in people with Type 1 and Type 2 diabetes. They have benefits for weight control because they help control appetite and delay hunger. Low Gl diets also reduce insulin levels and insulin resistance.
• carbohydrate breakdown (2) inhibiting glucose absorption and transport from the gut to the bloodstream
• enhancing glucose absorption and transport into muscle tissue inhibiting or reducing carbohydrates being stored as fat
• (5) inhibiting gluconeogenesis inhibiting or reducing carbohydrates being stored as fat
• (6) inhibiting or reducing carbohydrates being stored as fat
• pathways (2), (3), (5) and (6) To obtain weight loss and/or weight control, it is necessary to affect pathways (2) to (6).
• pathway (1 ) for the treatment of diabetes or to obtain weight loss, it is beneficial to do so.
• Bioflavonoids and in particular, flavanones and flavones are useful. Flavanones have the structure (I) shown below and flavones have the similar structure (II) shown below:
• R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently hydrogen, a hydroxy group, an alkoxy group, a rutinosyl group, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group.
• rhamnose-glucose L-rhamnose is linked ⁇ 1 - +2 to D-glucose "rhamnose-glucose, L-rhamnose is linked ⁇ 1 - +6 to D-glucose
• bioflavonoids affect all of the metabolic pathways, and those that affect a particular pathway are not equally effective. In addition, many of the bioflavonoids are easily oxidized and are not heat stable. As a food additive, many of the bioflavonoids are not suitable because they impart a bitter or adverse taste to the food at therapeutically effective amounts.
• the composition comprises a ratio of chlorogenic acid to quercetin to myricetin of about 1 :(2-4):(2-4), or about 1 :(2-3):(2-3), or about 1 :3:3 by weight.
• a composition comprising quercetin, myricetin and chlorogenic acid may be administered as a dietary supplement or as an additive to a foodstuff.
• the composition may be incorporated into a foodstuff that is later cooked or baked.
• the components of the composition are structurally stable to remain un-oxidized and are heat stable at temperatures required for baking or cooking.
• the composition When added to a carbohydrate-containing foodstuff in an effective amount, the composition enables a diabetic (or non-diabetic) person to consume the foodstuff without experiencing the same glycemic response as that of the foodstuff without the composition added thereto.
• the foodstuff may be converted from a high Gl (i.e., 70 or more) food to a medium Gl (i.e., 56-69) or low Gl (i.e., 55 or less) food, making the foodstuff safer for diabetics to consume.
• a high Gl i.e., 70 or more
• a medium Gl i.e., 56-69
• low Gl i.e., 55 or less
• Quercetin is a bioflavonoid found in many plants, including onions, celery, grapes, lemons, grapefruit and cranberries, to name a few.
• the primary metabolic pathway inhibition mechanism of quercetin is to cause GLUT2 transport inhibition, which slows glucose absorption from the gut.
• the secondary mechanism of quercetin is to cause glycogenosis by lipid hydrolysis, which releases glucose from adipose tissue.
• the tertiary mechanism of quercetin is to inhibit fatty acid synthase (lipogenesis), which reduces the body's ability to store glucose as fat.
• lipogenesis fatty acid synthase
• Myricetin is a bioflavonoid found in most berries, including cherry, cranberry and bilberry, and other plants, including parsley and rutabagas.
• the primary metabolic pathway inhibition mechanism of myricetin is to inhibit glucosidase, which inhibits or reduces the breakdown of starches, resulting in less available carbohydrates.
• the secondary mechanism of myricetin is to stimulate GLUT4 pathway, which enhances the uptake of glucose into muscle and skeletal tissue, resulting in less available glucose for storage as fat.
• the tertiary mechanism of quercetin is to inhibit the absorption of fructose. There are several methods by which the quercetin and/or myricetin may be harvested from their original botanical sources.
• extraction from botanical sources begins with a suitable seed material such as grape seeds or tomato seeds, pine bark or citrus rinds.
• the source material is macerated and flushed with water to separate the water soluble bioflavonoids from the bulkier pectins and fibers of the source material.
• This pulp wash is then treated with appropriate acids and bases as known in the art to cause precipitation.
• the precipitate is then washed again, dried and then concentrated to yield a fairly pure bioflavonoid composition. This composition may be further clarified to yield fractions containing the desired bioflavonoid product.
• reverse osmosis may be used to remove the target bioflavonoid by filtering it out of juice streams from beverage manufacturing processes.
• the process of manufacturing fruit juices such as citrus liberates the bioflavonoids from the rind and suspends them in the juice product. It is often desirable to remove these water soluble bioflavonoids because of their tendency to produce bitter or off flavors in the juice product.
• the primary grapefruit bioflavonoid naringin is released into the juice stream. Because naringin has a very distinct bitter taste, it is necessary to remove it from the product stream via the use of resin coated reverse osmosis devices to restore the proper flavor profile of the grapefruit juice.
• the resultant bioflavonoid is finally collected and dried to yield a fairly pure product.
• the flavonoids may also be manufactured by synthetic methods. Such methods may include an Allan-Robinson Reaction which is a chemical reaction of o- hydroxylaryl ketones with aromatic anhydrides to form flavanones. Another example is Auwers Synthesis, which is a procedure that requires an acid catalyzed aldol condensation between benzaldehyde and a 3-oxypentanon to an o- hydroxychalcone. Further bromination of the alkene group gives a dibromo-adduct that rearranges to a flavanol by reaction with potassium hydroxide.
• Allan-Robinson Reaction is a chemical reaction of o- hydroxylaryl ketones with aromatic anhydrides to form flavanones.
• Auwers Synthesis is a procedure that requires an acid catalyzed aldol condensation between benzaldehyde and a 3-oxypentanon to an o- hydroxychalcone. Further bromination of the alkene group gives a dibromo
• a further example is a Baker-Venkataraman Rearrangement, which involves the reaction of 2- acetoxyacetophenones with base to form 1 ,3-diketones. The rearrangement reaction proceeds via enolate formation followed by an acyl transper to form flavanones.
• An Algar-Flynn-Oyamada Reaction may also be used. In this reaction, a chalcone undergoes an oxidative cyclization to form a flavanol.
• Chlorogenic acid is one or more of a family of esters that form between certain cis or trans cinnamic acids and quinic acid. Chlorogenic acid may be subdivided by the identity, number and position of the acyl residues on the quinic acid. Examples of chlorogenic acid and functional analogs thereof may be represented by the formula (III):
• R r R 4 independently represents a cinnamic acid functional group represented by formulas (IV) to (VII).
• Cinnamic acids and their derivatives include a series of 3-phenyl-propenoic acids that differ in the chemical groups substituted on the aromatic ring.
• the most common of the cinnamic acids are caffeic acid, ferulic acid, sinapic acid and p- coumaric acid.
• Chlorogenic acid and several of its preferred functional analogs have the following chemical structures:
• the chlorogenic compound used is preferably derived from a natural occurring source, e.g., as an extract of one or more plants.
• a natural occurring source e.g., as an extract of one or more plants.
• it may be extracted from green coffee beans, green cacao beans, cinnamon, hawthorn, green tea, pome fruits such as apples and pears, stone fruits such as cherries and plums, berry fruits, citrus fruits, brassica vegetables such as kale, cabbage and brussel sprouts, solanaceae such as potato tubers, tomatoes and eggplant.
• It may also be derived from cereal grains such as oats, barley, rye, rice, corn and wheat. The amount and type of chlorogenic acid obtained depends upon the particular source.
• the primary metabolic pathway inhibition mechanism of chlorogenic acid is the inhibition of alpha-amylase, which inhibits the breakdown of complex carbohydrates into transportable form. The effect reduces the amount of carbohydrates that can be absorbed.
• the secondary mechanism is the inhibition of Glucose 6 phosphate, which reduces hepatic gluconeogenesis. It reduces the liver's ability to make glucose.
• a composition comprising about 50 to about 500 mg quercetin; about 50 to about 500 mg myricetin; and about 25 to about 150 mg chlorogenic acid.
• the composition comprises about 100 to about 200 mg quercetin; about 100 to about 200 mg quercetin; and about 30 to about 75 mg chlorogenic acid.
• the composition may be administered in the form of a dietary supplement, a food or beverage additive or as a pharmaceutical composition.
• the composition may include one or more additives.
• wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring agents, preservatives and antioxidants can also be present in the compositions.
• antioxidants examples include: (1 ) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like: (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
• water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
• oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT
• Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, each containing a predetermined amount of a compound of the present invention as an active ingredient.
• the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1 ) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as sodium citrate or dicalcium phosphate
• compositions may also comprise buffering agents.
• Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
• the composition is administered in the form of a beverage or foodstuff.
• the composition can be added to baked goods such as cookies, brownies, crackers, breakfast bar, energy bar, cereal and cake.
• the composition may be added to a fruit juice, a carbonated beverage, an energy drink, coffee or tea.
• the quercetin, myricetin and chlorogenic acid are heat stable and will not oxidize during storage.
• the individual components of the composition namely quercetin, myricetin and chlorogenic acid, do not have any direct chemical or physical reaction with the carbohydrates of the food consumed. Rather, the effect on carbohydrate metabolism is due to a direct chemical reaction of the components with the enzymes involved in carbohydrate metabolism. Therefore, the effects are determined by the chemical reaction rate, which in turn is determined by the concentration of the flavonoid components and the components of the enzymatic systems, such as GLUT2 and GLUT4.
• the effective concentration for a composition consisting of a 1 :3:3 mixture by weight of chlorogenic acid, myricetin and quercetin ranges from about 200 mg to about 500 mg of the composition consumed along with food.
• a single dose per day, taken at the beginning of the day is about 750 mg.
• the composition is administered as a dose three times a day in an amount of about 250 mg per dose.
• the total amount of the composition administered daily in one embodiment is at least 250 mg, or at least 500 mg, or at least 750 mg or at least 900 mg.
• the concentration of composition varies according to the type of food and the typical serving size of that food. For example, as illustrated below, the concentration of the composition varies as the food varies:
• the composition may be added to the beverage in an amount of about 0.5 to about 1.5 mg per ml of beverage.
• the composition may be added to the baked goods in an amount of about 2.5 mg to about 10 mg per gram of baked goods.
• inventive compositions and methods are illustrated in the following examples. These examples are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.
• 200 mg quercetin is administered orally to a subject 3 times per day, taken with food.
• Example 2 A tablet containing sodium citrate, 100 mg carboxymethylcellulose, 100 mg chlorogenic acid, 300 mg myricetin and 300 mg quercetin is administered orally once a day upon rising.
• Bread is manufactured to include 50 mg chlorogenic acid, 150 mg myricetin and 50 mg quercetin per 15 grams of total carbohydrates in the bread.
• Gingerbread cookies are manufactured to include 75 mg chlorogenic acid,
• Example 5 A 100 g sports power bar is manufactured to include 75 mg chlorogenic acid,
• a powder containing 50 mg chlorogenic acid, 100 mg myricetin and 100 mg quercetin is sprinkled onto foods such as, for example scrambled eggs after cooking but prior to consumption.
• Example 7 A powder containing 50 mg chlorogenic acid, 100 mg myricetin and 100 mg quercetin is sprinkled onto foods such as, for example scrambled eggs after cooking but prior to consumption.
• a composition containing a blend of 14% by weight chlorogenic acid, 52% by weight myricetin and 34% by weight quercetin is blended into a natural juice product, such as grapefruit juice, such that there is 1 mg of the composition per 1 g of juice.
• a natural juice product such as grapefruit juice
• a 1 :3:3 ratio by weight of chlorogenic acid, myricetin and quercetin is suspended in an elixir that is micro-encapsulated via air-suspension coating.
• the micro-encapsulated material is added to a brownie mix in an amount of 2 mg of microencapsulated material per 1 g of brownie.
• the brownie mix is sold as a dry mix for home or commercial baking, or the brownie is baked and sold as baked goods.
• a 1 :3:3 ratio by weight of chlorogenic acid, myricetin and quercetin is dissolved in a sucrose sugar solution. It is crystallized to form a table sugar that has the flavonoids incorporated into its structure.
• the sugar product is used as a flavoring in other foodstuffs as in standard sucrose sugar, from coffee to baked goods.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Hematology (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Botany (AREA)
• Child & Adolescent Psychology (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39590291

Family Applications (1)

Country Status (8)

Cited By (16)

Families Citing this family (16)

Citations (3)

Family Cites Families (12)

• 2008
  • 2008-03-11 JP JP2009554635A patent/JP2010522185A/ja active Pending
  • 2008-03-11 CN CN200880014120XA patent/CN101674821B/zh not_active Expired - Fee Related
  • 2008-03-11 EP EP08731870.5A patent/EP2129371B1/en active Active
  • 2008-03-11 CA CA002685031A patent/CA2685031A1/en not_active Abandoned
  • 2008-03-11 WO PCT/US2008/056474 patent/WO2008115723A1/en not_active Ceased
  • 2008-03-11 MX MX2009009996A patent/MX2009009996A/es active IP Right Grant
  • 2008-03-11 US US12/045,852 patent/US7943164B2/en active Active
  • 2008-03-11 BR BRPI0809047A patent/BRPI0809047B8/pt not_active IP Right Cessation
• 2011
  • 2011-01-27 US US13/014,798 patent/US8198319B2/en not_active Expired - Fee Related

Patent Citations (3)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events